MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Inspire Medical Systems EBITDA 2011-2026 | INSP
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Inspire Medical Systems
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.9 M | 42.6 M | -37.4 M | -45.7 M | -38.6 M | -55.4 M | -34.4 M | -20 M | -15.7 M | -17.2 M | -19.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.9 M | -55.4 M | -16 M |
Quarterly EBITDA Inspire Medical Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.3 M | 84 K | 1.56 M | - | 16.2 M | 6.5 M | -14.4 M | - | -12.7 M | -15.9 M | -18.9 M | - | -16.7 M | -13.6 M | -15.7 M | - | -8.92 M | -12.2 M | -15.5 M | - | -9.3 M | -22.4 M | -16.3 M | - | -8.31 M | -7.97 M | -8.67 M | - | -4.36 M | -5.45 M | -5.1 M | - | -3.48 M | -4.28 M | -4.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 M | -22.4 M | -7.65 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
Xtant Medical Holdings
XTNT
|
-7.85 M | $ 0.55 | -2.31 % | $ 73.5 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
2.28 B | $ 88.57 | -0.65 % | $ 18 B | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 10.93 | -5.12 % | $ 1.64 B | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Accuray Incorporated
ARAY
|
14 M | $ 0.4 | 4.21 % | $ 41.1 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 34.58 | -5.62 % | $ 1.07 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.59 | -1.18 % | $ 32.1 M | USA |
 |
Aethlon Medical
AEMD
|
-9 M | $ 2.15 | -5.29 % | $ 3.36 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 79.34 | -3.36 % | $ 46.4 B | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 11.2 | -1.84 % | $ 1.51 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.52 | -5.08 % | $ 364 M | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
-26.5 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
-13.5 M | $ 0.7 | 2.32 % | $ 29.3 M | USA |
 |
Penumbra
PEN
|
207 M | $ 335.1 | -0.39 % | $ 13 B | USA |
 |
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.17 | -5.65 % | $ 47.6 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | USA |
 |
Surgalign Holdings
SRGA
|
-76.3 M | - | -32.98 % | $ 1.68 M | USA |
 |
STRATA Skin Sciences
SSKN
|
-2.25 M | - | - | $ 6.6 M | USA |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
AVITA Medical
RCEL
|
-40.2 M | $ 3.82 | -1.04 % | $ 106 M |  Australia |
 |
AxoGen
AXGN
|
-1.19 M | $ 31.28 | -3.01 % | $ 1.44 B | USA |
 |
Delcath Systems
DCTH
|
898 K | $ 8.97 | -1.75 % | $ 321 M | USA |